证券代码：003017 股票简称：大洋生物 公告编号：2023-084 浙江大洋生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获得补助的基本情况 2023 年 4 月 1 日至 6 月 30 日，浙江大洋生物科技集团股份有限公司（以下 简称"大洋生物"或"公司"）及其下属全资子公司建德市恒洋化工有限公司、 浙江舜跃生物科技有限公司（以下分别简称"恒洋化工"、"浙江舜跃"）累计 收到政府补助金额为人民币 4,759,270.66 元，具体补助情况详见附件。 二、补助的类型及其对上市公司的影响公司 1、补助的类型 根据《企业会计准则第 16 号—政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相关 的政府补助，是指除与资产相关的政府补助之外的政府补助。公司上述获得的政 府补助不用于购建或以其他方式形成长期资产，故为与收益相关的政府补助。 2、补助的确认和计量 根据《企业会计准则第 16 号—政府补助》的规定，上述政府补助属于与公 司日常活动相关的政府补助，计入其他收益或递延 ...

浙江大洋生物科技集团股份有限公司 证券代码：003017 股票简称：大洋生物 公告编号：2023-072 关于使用部分闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司"、"本公司"或 "大洋生物"）于 2022 年 10 月 21 日召开第五届董事会第八次会议、第五届监 事会第六次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管理的 议案》。根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规 范运作》等有关规定，为充分利用公司闲置募集资金，提高资金利用率，在不影 响募投项目建设使用的前提下，公司（含子公司福建舜跃科技股份有限公司，以 下简称"福建舜跃"）使用最高额度不超过 23,000.00 万元（含本数）闲置募集 资金进行现金管理（在此额度内可滚动使用），自董事会审议通过之日起 12 个月 之内有效。具体内容详见公司在《证券时报》、《证券日报》、《上海证券报》、《中 国证券报》和巨潮资讯网（http://www.cninfo.com.cn）上披露的 ...

证券代码：003017 证券简称：大洋生物 浙江大洋生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|----------------------------------|--------------|----------------------| | | | | 编号：2023-001 | | 投资者关系活动 | □特定对象调研 | 分析师会议 | | | 类别 | □ 媒体采访 √ | 业绩说明会 | | | | □ 新闻发布会 | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | | | | 参与单位名称及 | | | | | | 投资者网上提问 | | | | 人员姓名 | | | | | 时间 | 2023 年 5 月 12 日( | )15:00~17:00 | | | 地点 | | | https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | | | 上市公司接待人 | 1、董事长兼总经理陈阳贵 | | | | 员姓名 | 2、财务总监陈旭君 | | ...

证券代码：003017 股票简称：大洋生物 公告编号：2023-048 浙江大洋生物科技集团股份有限公司 关于参加浙江辖区上市公司 2023 年投资者网上集体接待日活动 暨 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，提升公司投资者关系管理水平，浙江大 洋生物科技集团股份有限公司（以下简称"公司"）将参加由浙江证监局、浙江 省上市公司协会与深圳市全景网络有限公司联合举办的"2023 年浙江辖区上市 公司投资者集体接待日活动"暨 2022 年度业绩说明会，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2023 年 5 月 12 日（周五）15:00-17:00。届时， 公司董事长兼总经理陈阳贵先生、董事会秘书徐旭平先生、财务总监陈旭君女士、 独立董事姜晏先生（如遇特殊情况，参与人员会有调整），将通过互动平台与投 资者进行网络沟通和 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,058,104,944.77, representing a 35.10% increase compared to CNY 783,209,277.95 in 2021[20] - The net profit attributable to shareholders for 2022 was CNY 80,726,948.90, up 15.31% from CNY 70,009,323.58 in the previous year[20] - The net cash flow from operating activities improved significantly to CNY 91,886,561.61, a 361.37% increase from a negative CNY 35,156,142.54 in 2021[20] - Basic earnings per share rose to CNY 1.3872, an 18.89% increase from CNY 1.1668 in 2021[20] - Total assets at the end of 2022 were CNY 1,507,973,920.76, reflecting a 9.72% increase from CNY 1,374,346,748.42 at the end of 2021[20] - The company's net assets attributable to shareholders decreased slightly by 0.57% to CNY 985,049,427.99 from CNY 990,709,384.09 in 2021[20] - The company reported a decrease of 4.87% in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to CNY 55,170,120.29 in 2022[20] - The weighted average return on equity for 2022 was 8.46%, an increase of 1.25% from 7.21% in 2021[20] Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.0 per 10 shares, totaling CNY 12,000,000 based on 60,000,000 shares[3] - The cash dividend distribution accounts for 100% of the total distributable profit of 317,244,493.46 yuan[176] Production Capacity and Market Position - The company holds an 8.5 million ton production capacity for potassium carbonate, accounting for 9.7% of global production capacity[33] - The global production capacity for potassium bicarbonate was 47,000 tons in 2022, with the company being one of the major producers alongside Armand Products Company and Evonik[33] - The company is positioned as a leading supplier of fluorinated fine chemicals in the domestic and international markets due to the exit of competitors[34] - The company is a leading player in the potassium carbonate and potassium bicarbonate industry, recognized as a national high-tech enterprise and has 40 invention patents and 8 utility model patents[41] - The company has solidified its position in the potassium salt market with the completion of a project that produces 25,000 tons of potassium carbonate and 15,000 tons of potassium bicarbonate, accounting for 36.36% of the domestic potassium carbonate capacity[51] Environmental Compliance and Initiatives - The company has successfully completed environmental assessments for its new production projects, including a 25,000-ton potassium carbonate and 15,000-ton potassium bicarbonate project[39] - The company has invested in environmental protection, adhering to the principles of reduction, reuse, and recycling, and has optimized production processes to reduce emissions of "three wastes"[193] - The wastewater treatment facility has a capacity of 1500 m³/d, complying with the GB21904-2008 standard for chemical synthesis pharmaceutical industry wastewater discharge[194] - The company has implemented a waste gas treatment system that meets ultra-low emission standards, utilizing low nitrogen combustion technology and various purification methods[195] - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental authority[197] Research and Development - The company has five invention patents and two non-patent technologies related to potassium carbonate production, enhancing its competitive edge[38] - Research and development expenses increased by 22.36% to CNY 34.06 million, indicating a focus on innovation[69] - The company is committed to enhancing its research and development capabilities and expanding its product offerings in the fluorine chemical sector[110] Sales and Market Expansion - Domestic sales accounted for 81.90% of total revenue, with a year-on-year growth of 39.13%[58] - The company's self-operated product export revenue reached CNY 154.69 million, an increase of 15.82% compared to the previous year[62] - The trade product export revenue was CNY 36.88 million, reflecting a growth of 37.52% year-on-year[62] - The company plans to enter two new markets in Southeast Asia by the end of 2023, aiming to capture an additional 5% market share[149] Corporate Governance - The company has established a governance mechanism with independent directors and a supervisory board to oversee management effectively[182] - The board of directors and supervisory board operate independently, adhering to legal and regulatory requirements[121] - The company has implemented a robust internal control system that covers all operational aspects, ensuring compliance and effective governance[125] Employee Management - The total number of employees at the end of the reporting period was 897, with 570 in the parent company and 327 in major subsidiaries[167] - The company encourages innovation and provides a promotion path linked to compensation for employees who contribute significantly in management, operations, and technology[172] - The employee compensation system includes annual salary, hourly wage, and piece-rate systems, with annual salary being the primary method for senior management[168][169] Financial Management - The company has established a financial derivatives trading management system to effectively regulate investment behavior and control risks associated with financial derivatives[87] - The company has closely monitored legal regulations related to financial derivatives to mitigate potential legal risks[87] - The company has committed to projects with a total investment of 178.68 million CNY, with 82.67% of the investment completed by June 30, 2022[92] Market Trends and Product Development - The demand for hydrochloride amprolium is on the rise, driven by increased per capita consumption of chicken and the growth of large-scale livestock farming[32] - The company is focusing on expanding its product applications in high-end fields such as food, pharmaceuticals, and agriculture[33] - The company is developing a new series of trifluoroacetyl products, which will be used in various pharmaceutical intermediates, including treatments for diabetes and COVID-19[110] Risk Management - The company has identified certain risks in the production process of fluorobenzene products, which may affect continuous production due to equipment material compliance issues[93] - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental authority[197]

Financial Performance - The company's revenue for Q1 2023 was ¥251,292,978.42, representing a 29.50% increase compared to ¥194,049,118.38 in the same period last year[5] - Net profit attributable to shareholders increased by 130.06% to ¥19,396,982.24 from ¥8,431,349.53 year-on-year[5] - The net profit after deducting non-recurring gains and losses surged by 208.04% to ¥16,857,203.39 from ¥5,472,352.56 in the previous year[5] - The basic and diluted earnings per share rose by 142.86% to ¥0.34 from ¥0.14 in the same quarter last year[5] - Total operating revenue for Q1 2023 was CNY 251,292,978.42, an increase of 29.5% compared to CNY 194,049,118.38 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 19,396,982.24, representing a significant increase of 130.5% from CNY 8,431,349.53 in Q1 2022[20] - The company reported a total profit of CNY 21,491,572.34 for Q1 2023, an increase of 131.5% from CNY 9,298,059.67 in the same period last year[20] Cash Flow and Assets - The net cash flow from operating activities improved by 42.57%, reaching -¥22,210,464.08 compared to -¥38,672,236.24 in the previous year[10] - The company's current assets totaled CNY 756,131,103.20, up from CNY 728,163,051.42, indicating an increase of about 3.8%[16] - The cash and cash equivalents decreased to CNY 96,847,409.95 from CNY 131,111,370.93, representing a decline of approximately 26.0%[16] - Cash flow from operating activities showed a net outflow of CNY 22,210,464.08, an improvement from a net outflow of CNY 38,672,236.24 in Q1 2022[23] - Cash flow from investing activities resulted in a net outflow of CNY 48,847,080.83, slightly better than the net outflow of CNY 50,422,671.88 in the previous year[24] - Cash flow from financing activities generated a net inflow of CNY 38,786,348.38, compared to a net inflow of CNY 7,518,397.75 in Q1 2022[24] - The ending cash and cash equivalents balance for Q1 2023 was CNY 96,847,409.95, an increase from CNY 50,191,666.37 at the end of Q1 2022[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,532,488,497.61, a 1.63% increase from ¥1,507,973,920.76 at the end of the previous year[5] - The company's short-term borrowings rose to CNY 295,320,000.00 from CNY 252,114,104.19, marking an increase of about 17.1%[17] - The total liabilities increased slightly to CNY 527,313,683.25 from CNY 522,924,492.77, showing a marginal rise of approximately 0.7%[17] - The equity attributable to the owners of the parent company reached CNY 1,005,174,814.36, up from CNY 985,049,427.99, reflecting an increase of about 2.3%[17] Investments and Shareholder Information - The company reported a significant increase in long-term equity investments by 259.91%, amounting to ¥9,000,893.39 from ¥2,500,893.39[9] - The number of ordinary shareholders at the end of the reporting period was 10,287[12] Operational Developments - The company plans to implement a project for producing 50,000 tons/year of potassium carbonate from fly ash, which has received preliminary approval from the Hangzhou Ecological Environment Bureau[14] - Zhejiang Dayang completed the merger with its wholly-owned subsidiary Shanghai Taiyang Chemical Co., Ltd., optimizing its management structure and improving operational efficiency[14] Inventory and Receivables - The company reported an increase in accounts receivable to CNY 76,896,923.33 from CNY 68,990,582.76, which is an increase of approximately 11.0%[16] - Inventory levels rose to CNY 138,843,313.02 from CNY 126,871,327.15, indicating an increase of about 9.4%[16] Research and Development - Research and development expenses for Q1 2023 totaled CNY 8,499,851.91, up 28.9% from CNY 6,594,699.94 in Q1 2022[19]

Group 1: Company Performance and Financials - The company reported a projected profit growth of 10%-30% for the year based on previous year's performance [3] - The capital reserve for 2021 was 564 million, indicating potential for capital increase [2] - The company is actively repurchasing shares as part of its stock incentive or employee stock ownership plan [2] Group 2: Production Capacity and Projects - The first phase of the Fujian subsidiary has an annual production capacity of 1,500 tons for 2-chloro-6-fluorobenzaldehyde and other aromatic hydrocarbon products [2] - The second phase of the trifluoroacetyl series includes 3,800 tons of trifluoroethyl acetate and other products [2] - The trifluoroacetyl series products are expected to start production in September 2023 [2] Group 3: Market and Raw Material Impact - The company is adjusting the sales prices of end products to mitigate the impact of rising raw material costs [3] - The company is monitoring the market demand for its products and adjusting production accordingly [5] - The pandemic has not significantly affected the procurement and transportation of potassium chloride raw materials [4] Group 4: Project Development and Regulatory Compliance - The trifluoroacetyl project is currently in the preparatory approval stage [4] - The company is addressing technical issues related to the production capacity utilization rate, which is approximately 60% [4] - The company is committed to complying with safety and environmental regulations in optimizing its production processes [4]

Financial Performance - The company's revenue for Q3 2022 was ¥242,531,168.58, representing a year-on-year increase of 33.39%[5] - The net profit attributable to shareholders for Q3 2022 was ¥12,759,085.37, a decrease of 24.73% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was ¥0.21, down 25.00% year-on-year[5] - Total operating revenue for Q3 2022 reached ¥735,173,544.19, an increase of 29.5% compared to ¥567,734,774.83 in Q3 2021[18] - The net profit for the third quarter of 2022 was CNY 50,100,877.55, a decrease of 28% compared to CNY 69,485,757.87 in the same period last year[19] - The total revenue from operating activities was CNY 707,227,132.03, up 21.2% from CNY 583,805,084.65 in the previous year[20] - The company reported a total comprehensive income of CNY 50,100,877.55 for the quarter, reflecting a decrease from CNY 69,485,757.87 in the previous year[19] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥1,401,617,860.79, reflecting a 1.98% increase from the end of the previous year[5] - Total current assets as of September 30, 2022, were ¥668,092,074.40, a decrease of 10% from ¥742,699,144.12 at the beginning of the year[16] - Total liabilities increased to ¥483,225,644.86, up 26.1% from ¥383,637,364.33 at the start of the year[16] - Total equity attributable to shareholders decreased to ¥918,392,215.93 from ¥990,709,384.09, a decline of 7.3%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥60,849,462.15, showing a slight decrease of 0.29%[5] - The cash flow from operating activities showed a net increase of CNY 60,849,462.15, slightly down from CNY 61,025,112.94 in the previous year[20] - The cash flow from investment activities resulted in a net outflow of CNY 119,529,791.00, worsening from a net outflow of CNY 53,144,434.47 in the previous year[21] - The cash and cash equivalents net increase decreased by 192.80% to -¥87,936,337, due to reduced cash flow from investment activities[9] - Cash and cash equivalents decreased to ¥46,555,246.48 from ¥131,883,363.13, a decline of 64.7%[16] Operating Costs and Expenses - The company's operating costs increased by 41.88% to ¥630,401,867 due to rising raw material prices for main products[9] - Total operating costs for Q3 2022 were ¥706,453,483.97, up 38.3% from ¥510,878,636.15 in the same period last year[18] - R&D expenses rose by 44.45% to ¥26,378,606, attributed to new R&D project investments[9] - Research and development expenses increased to ¥26,378,606.21, representing a 44.5% rise from ¥18,261,132.56 in the previous year[18] Investments and Gains - The company recognized a total of ¥1,456,124.29 in non-recurring gains and losses for the current period[6] - Investment income fell by 63.54% to ¥3,190,358, primarily due to reduced returns from RMB financial products and foreign exchange forward contracts[9] - The net cash flow from investment activities decreased by 124.91% to -¥119,529,791, reflecting increased net investments in structured deposits[9] Borrowings and Financial Position - The company’s short-term borrowings increased by 69.00% to ¥235,026,250.00 due to liquidity needs[8] - Financial expenses decreased by 65.13% to ¥1,008,386, mainly due to increased foreign exchange gains[9] - The deferred income tax liabilities increased by 70.68% to ¥27,667,039 due to one-time deductions for equipment[9] Other Notable Changes - The company reported a significant increase in accounts receivable by 49.12%, reaching ¥51,093,685.21[8] - The company reported a significant increase in credit impairment losses by 701.30% to -¥629,662, reflecting higher bad debt provisions[9] - The deferred income increased by 31.17% to ¥12,586,885, mainly from government subsidies related to assets[9] - The company signed an investment framework agreement with the Shandong Linshu Economic Development Zone for a potassium carbonate project on September 26, 2022[13] - The company did not conduct any audited review of the third-quarter report[22]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥492,642,375.61, representing a 27.65% increase compared to ¥385,920,462.02 in the same period last year[19]. - The net profit attributable to shareholders decreased by 28.92% to ¥37,341,792.18 from ¥52,534,375.83 year-on-year[19]. - Basic and diluted earnings per share fell by 28.41% to ¥0.63 from ¥0.88 in the same period last year[19]. - The total assets at the end of the reporting period increased by 3.90% to ¥1,427,991,014.33 from ¥1,374,346,748.42 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 8.59% to ¥905,628,960.92 from ¥990,709,384.09 at the end of the previous year[19]. - The company reported a total of ¥3,954,884.16 in non-recurring gains and losses during the reporting period[24]. - The weighted average return on net assets was 3.80%, down from 5.37% in the previous year[19]. - The cost of sales increased by 38.62% to ¥416,338,080.14, primarily due to significant rises in raw material and coal prices[47]. - Research and development investment surged by 109.99% to ¥21,142,050.06, reflecting the company's commitment to new project investments[47]. - The net cash flow from operating activities turned negative at -¥29,603,598.59, a decline of 269.67% compared to ¥17,447,589.95 in the previous year[19]. Market and Product Development - The company’s comprehensive annual production capacity for potassium carbonate (including potassium bicarbonate) will reach 100,000 tons following the completion of its investment project[29]. - The market demand for potassium bicarbonate is gradually increasing, particularly in the food and livestock sectors[28]. - The company has developed a "closed-loop ion exchange system" for potassium carbonate production, achieving complete recycling of production water[38]. - The company’s product quality has been recognized in the market, with no disputes arising from quality issues during the reporting period[41]. - The company’s salt acid aminopropyl production project has been recognized as a "National Torch Program Industrialization Demonstration Project"[40]. - The company achieved a significant increase in sales from the inorganic salt product line, which generated ¥374,992,901.91, accounting for 76.12% of total revenue[50]. Risk Management and Compliance - The company has outlined potential risks and corresponding mitigation measures in the report[3]. - The company has established a financial derivatives trading management system to effectively regulate investment behavior and control risks associated with financial derivatives[62]. - The company aims to mitigate risks related to exchange rate fluctuations through financial derivatives, enhancing its competitive edge[62]. - The company has implemented measures to prevent risks associated with single-person operations in financial derivatives trading[62]. - The company has outlined potential risks including market risk, internal control risk, and customer default risk, along with corresponding control measures[61]. Environmental and Safety Measures - The company emphasizes the importance of safety and environmental protection in its production processes to mitigate risks associated with the chemical industry[78]. - The company has a wastewater treatment facility with a capacity of 1500 m³/day, meeting the strictest discharge standards[92]. - The company implemented a low-nitrogen combustion technology and a flue gas denitrification system to meet emission standards[94]. - The company has established a leakage detection and repair (LDAR) system to control VOCs emissions effectively[94]. - The company reported no significant environmental pollution incidents during the reporting period[91]. - The company’s environmental facilities are operating normally, with all pollutant discharge indicators meeting standards[91]. - The company has a comprehensive emergency response plan for environmental incidents, regularly updated and filed with local authorities[97]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[4]. - The company has not implemented any stock incentive plans during the reporting period[85]. - The company has made significant efforts to enhance information disclosure and protect the rights of shareholders and creditors, ensuring fair access to company information[105]. - The company is committed to timely and full disclosure of any inability to fulfill commitments, along with the reasons for such failures[124]. - The company will bear legal liability for any losses incurred by investors due to non-fulfillment of commitments, including compensatory measures[126]. - The company’s management will not receive any salary increases or bonuses if they fail to meet their obligations[126]. Financial Position and Investments - Cash and cash equivalents decreased to ¥109,030,514.26, accounting for 7.64% of total assets, down from 9.60% last year, a decrease of 1.96%[54]. - Accounts receivable increased to ¥49,370,005.44, representing 3.46% of total assets, up from 2.49% last year, an increase of 0.97% due to higher sales volume[54]. - Inventory rose to ¥180,619,435.17, making up 12.65% of total assets, compared to 11.76% last year, an increase of 0.89%[54]. - The total value of restricted assets at the end of the reporting period was ¥144,235,782.77, primarily due to bank loan collateral requirements[59]. - The company reported a total fundraising amount of RMB 38,269.69 million, with RMB 1,235.20 million utilized in the current period and RMB 15,247.16 million cumulatively used[63]. - The company has invested RMB 12.35 million in the carbon potassium and hydrogen potassium projects, achieving a progress rate of 66.18%[67]. - The company has a structured bank deposit balance of RMB 226 million, which is part of the unused fundraising[68]. Operational Efficiency and Future Outlook - The company aims to enhance brand influence and optimize product structure to meet diverse market demands and improve customer loyalty[79]. - The company plans to maintain reasonable inventory levels and seek deep cooperation with upstream suppliers to mitigate risks from raw material price fluctuations[77]. - The company plans to utilize up to RMB 250 million of idle fundraising for cash management, ensuring project funding needs are met[68]. - The company has a plan to stabilize its stock price through share buybacks, which will be executed in compliance with relevant laws and regulations[126]. - The company will announce its shareholding increase plan within two trading days after the stabilization conditions are triggered[130].

Financial Performance - The company's revenue for Q1 2022 was ¥194,049,118.38, representing a 9.83% increase compared to ¥176,677,783.46 in the same period last year[3] - Net profit attributable to shareholders decreased by 66.56% to ¥8,431,349.53 from ¥25,212,102.44 year-on-year[3] - Basic and diluted earnings per share dropped by 66.67% to ¥0.14 from ¥0.42 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 194,049,118.38, an increase of 9.76% compared to CNY 176,677,783.46 in Q1 2021[21] - Net profit for Q1 2022 was CNY 8,431,349.53, a decrease of 66.51% from CNY 25,212,102.44 in Q1 2021[22] - The company reported a total comprehensive income of CNY 8,431,349.53 for Q1 2022, compared to CNY 25,212,102.44 in Q1 2021[22] Cash Flow - The net cash flow from operating activities was negative at -¥38,672,236.24, a decline of 1,441.19% compared to ¥2,883,434.02 in the previous year[3] - Cash flow from operating activities for Q1 2022 was negative CNY 38,672,236.24, compared to positive CNY 2,883,434.02 in Q1 2021[24] - The net cash flow from investment activities was -50,422,671.88 CNY, compared to -27,776,723.43 CNY in the previous period, indicating a decline in investment performance[25] - The net cash flow from financing activities was 7,518,397.75 CNY, an improvement from -591,000.00 CNY in the previous period, reflecting better financing management[25] - The total cash and cash equivalents at the end of the period were 50,191,666.37 CNY, down from 131,883,363.13 CNY at the beginning of the period, showing a significant decrease in liquidity[25] - The net increase in cash and cash equivalents was -81,691,696.76 CNY, compared to -25,527,073.96 CNY in the previous period, indicating worsening cash flow[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,355,019,806.57, down 1.41% from ¥1,374,346,748.42 at the end of the previous year[3] - As of March 31, 2022, the total current assets amounted to CNY 702,968,250.43, a decrease of 5.2% from CNY 742,699,144.12 at the beginning of the year[17] - The total liabilities as of March 31, 2022, were CNY 703,968,000, with short-term borrowings increasing to CNY 169,071,435.55, up from CNY 139,071,435.55 at the beginning of the year, indicating a rise of 21.6%[17] - Total liabilities as of Q1 2022 were CNY 376,106,626.88, a slight decrease from CNY 383,637,364.33 at the end of the previous period[21] - Total equity attributable to shareholders of the parent company was CNY 978,913,179.69, down from CNY 990,709,384.09 in the previous period[21] Research and Development - Research and development expenses increased by 58.35% to ¥6,594,699.94 compared to ¥4,164,681.97 in the previous year[9] - Research and development expenses for Q1 2022 were CNY 6,594,699.94, an increase of 58.00% from CNY 4,164,681.97 in Q1 2021[21] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[14] Share Repurchase - The company has repurchased a total of 587,900 shares through a special securities account, accounting for 0.9798% of the total share capital[14] - The company plans to repurchase between 1.4 million to 2.8 million shares with a budget of CNY 63 million to CNY 126 million within 12 months from the board's approval date[14] Inventory and Receivables - The accounts receivable increased to CNY 49,633,849.80 from CNY 34,263,864.88, reflecting a growth of 44.9%[16] - The inventory balance rose to CNY 183,125,642.46, up from CNY 161,607,940.34, marking an increase of 13.3%[16] Financial Management - The company experienced a 125.72% rise in financial expenses, totaling ¥1,394,897.91 due to increased bank acceptance bill discounting interest[9] - The weighted average return on equity decreased to 0.85% from 2.60% in the same period last year[3] Audit Status - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[26]